D.E. Shaw & Co
ENTA icon

D.E. Shaw & Co’s Enanta Pharmaceuticals ENTA Stock Holding History

D.E. Shaw & Co’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$895K Sell
70,884
-96,830
-58% -$1.3M ﹤0.01% 3517
2025
Q4 		$2.64M Sell
167,714
-58,030
-26% -$737K ﹤0.01% 2823
2025
Q3 		$2.7M Sell
225,744
-56,532
-20% -$452K ﹤0.01% 2746
2025
Q2 		$2.13M Sell
282,276
-101,044
-26% -$608K ﹤0.01% 2695
2025
Q1 		$2.12M Sell
383,320
-38,274
-9% -$236K ﹤0.01% 2565
2024
Q4 		$2.42M Sell
421,594
-79,778
-16% -$765K ﹤0.01% 2576
2024
Q3 		$5.19M Sell
501,372
-32,809
-6% -$429K ﹤0.01% 1915
2024
Q2 		$6.93M Sell
534,181
-36,065
-6% -$487K 0.01% 1611
2024
Q1 		$9.96M Sell
570,246
-67,922
-11% -$899K 0.01% 1362
2023
Q4 		$6.01M Buy
638,168
+277,116
+77% +$2.58M 0.01% 1763
2023
Q3 		$4.03M Buy
361,052
+308,503
+587% +$4.97M ﹤0.01% 2000
2023
Q2 		$1.12M Buy
+52,549
New +$1.55M ﹤0.01% 3012
2023
Q1 		– Sell
-4,741
Closed -$221K – 4554
2022
Q4 		$221K Hold
4,741
– – ﹤0.01% 4208
2022
Q3 		$246K Hold
4,741
– – ﹤0.01% 4387
2022
Q2 		$224K Sell
4,741
-1,364
-22% -$74K ﹤0.01% 4497
2022
Q1 		$435K Sell
6,105
-18,403
-75% -$1.2M ﹤0.01% 4453
2021
Q4 		$1.83M Buy
24,508
+14,172
+137% +$1.11M ﹤0.01% 3428
2021
Q3 		$587K Sell
10,336
-14,404
-58% -$712K ﹤0.01% 3991
2021
Q2 		$1.09M Sell
24,740
-16,444
-40% -$805K ﹤0.01% 3460
2021
Q1 		$2.03M Buy
41,184
+18,975
+85% +$946K ﹤0.01% 2566
2020
Q4 		$935K Sell
22,209
-2,117
-9% -$93.1K ﹤0.01% 3064
2020
Q3 		$1.11M Buy
24,326
+9,512
+64% +$461K ﹤0.01% 2787
2020
Q2 		$744K Buy
+14,814
New +$767K ﹤0.01% 3129
2020
Q1 		– Sell
-8,068
Closed -$430K – 4011
2019
Q4 		$498K Sell
8,068
-3,229
-29% -$200K ﹤0.01% 3398
2019
Q3 		$679K Buy
11,297
+8,614
+321% +$640K ﹤0.01% 3057
2019
Q2 		$226K Buy
+2,683
New +$241K ﹤0.01% 3422
2019
Q1 		– Sell
-5,250
Closed -$372K – 3676
2018
Q4 		$372K Sell
5,250
-1,200
-19% -$92K ﹤0.01% 3249
2018
Q3 		$551K Sell
6,450
-25,815
-80% -$2.59M ﹤0.01% 3053
2018
Q2 		$3.74M Buy
32,265
+1,974
+7% +$197K ﹤0.01% 1733
2018
Q1 		$2.45M Buy
30,291
+16,917
+126% +$1.3M ﹤0.01% 1916
2017
Q4 		$785K Sell
13,374
-6,258
-32% -$313K ﹤0.01% 2722
2017
Q3 		$919K Sell
19,632
-19,104
-49% -$768K ﹤0.01% 2534
2017
Q2 		$1.39M Buy
38,736
+22,930
+145% +$733K ﹤0.01% 2204
2017
Q1 		$487K Sell
15,806
-15,184
-49% -$473K ﹤0.01% 2749
2016
Q4 		$1.04M Sell
30,990
-56,349
-65% -$1.62M ﹤0.01% 2433
2016
Q3 		$2.32M Buy
+87,339
New +$2.03M ﹤0.01% 1817
2014
Q4 		– Sell
-5,673
Closed -$224K – 4063
2014
Q3 		$224K Buy
+5,673
New +$226K ﹤0.01% 3841

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co's ENTA Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Enanta Pharmaceuticals (ENTA) stake by 58% in Q1 2026, selling an estimated $1.3M and leaving 70,884 shares worth $895K. The position accounts for ﹤0.01% of the portfolio, ranked #3517.

D.E. Shaw & Co first reported a position in ENTA in Q3 2014 and has held it in 37 quarters since. The position peaked at $9.96M in Q1 2024. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • D.E. Shaw & Co held 70,884 shares of Enanta Pharmaceuticals worth $895K as of Q1 2026.
  • D.E. Shaw & Co sold 96,830 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1.3M.
  • Enanta Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3517 holding.
  • D.E. Shaw & Co first reported a position in Enanta Pharmaceuticals in Q3 2014 and has held it in 37 quarters since.
  • D.E. Shaw & Co's Enanta Pharmaceuticals position peaked at $9.96M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.